| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 48.8 | 32.1 |
| Profit before tax | -184.6 | -67.3 |
| Net income | -184.6 | -67.3 |
| EPS (diluted, $ a share) | $-0.18 | $-0.07 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +52.3% |
|---|---|
| Operating margin | -159.7% |
10-Q filed with the SEC, NASDAQ: IBRX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
ImmunityBio, Inc.: key numbers
- Share price
- $5.98Close, Nov 16
- Market cap
- $6.36B
- Shares outstanding
- 1.06BLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from ImmunityBio, Inc.
All →ImmunityBio Financial Results
ImmunityBio reported Q3 2026 net product revenue of $48.7 million, a 53% increase year-over-year, driven by the adoption of ANKTIVA in the U.S. The company also highlighted a recent FDA label expansion for ANKTIVA and positive topline results from its QUILT-2.005 trial in BCG-naïve bladder cancer patients.
- Term
- Q3 2026
ImmunityBio Clinical Trial Data
ImmunityBio announced that its QUILT-2.005 trial of ANKTIVA plus BCG met its primary efficacy endpoint in patients with BCG-naïve non-muscle invasive bladder cancer (NMIBC). The combination therapy showed a statistically significant improvement in efficacy compared to BCG alone, and the company plans to submit a supplemental Biologics License Application (sBLA) to the FDA by year-end 2026.
ImmunityBio Regulatory Approval
The FDA has expanded the approved indication for ImmunityBio's ANKTIVA in combination with BCG to include patients with BCG-unresponsive NMIBC with papillary-only tumors. This follows the initial April 2024 approval and broadens the addressable patient population to include all patients with BCG-unresponsive NMIBC, a group that represents approximately 85% of the NMIBC population.
ImmunityBio Insider Barry J. Simon Sells $269K of Stock
Barry J. Simon sold 25,000 shares of ImmunityBio, Inc. at $10.75 a share, worth $269K in total on Oct 5, 2026. Shares held after the trade: 2,777,788 (-0.9%).
- Value
- $269K
- Shares
- 25,000
- Price
- $10.75
- Holding change
- -0.9%
- Trade date
- Oct 5, 2026
ImmunityBio Insider Cheryl Cohen Sells $851K of Stock
Cheryl Cohen sold 81,056 shares of ImmunityBio, Inc. at $10.50 a share, worth $851K in total on Oct 2, 2026. Shares held after the trade: 100,309 (-44.7%).
- Value
- $851K
- Shares
- 81,056
- Price
- $10.50
- Holding change
- -44.7%
- Trade date
- Oct 2, 2026